Granules India's shares fell nearly 8% after the US FDA issued a warning letter regarding its Gagillapur facility, citing ...

Granules added that manufacturing and distribution of its existing products at the facility will continue unaffected.

"On February 26, 2025, the US FDA issued a Warning Letter to Granules' Gagillapur facility based on its inspection conducted ...

HYDERABAD: In a major setback to Hyderabad-based pharma player Granules India Ltd, the US Food and Drug Administration (USFDA ...

Drug firm Granules India Ltd on Thursday (February 27) announced that the US FDA has issued a Warning Letter for its ...

The development may temporarily delay the approval of pending product submissions from the site, but existing manufacturing ...

In a bid to break into the CDMO business at one of its most lucrative angles, India's Granules is snapping up Swiss contract ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

The Warning Letter is dated February 26, 2025 and the facility continues to hold an "Official Action Indicated" (OAI) status.

Granules India's Gagillapur facility receives FDA warning letter, impacting product submissions review until resolved, company remains confident in resolution.

Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation ...

Is it farewell to the flat white and so long to macchiato? According to a recent study by Deloitte, we still love our instant ...